UY28897A1 - ACID 2 - ((2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL) AMINO) -3- (PHENYLPIRIDIN-2-ILAMINO) SUBSTANTIALLY PURE PROPIONIC AS INHIBITOR OF THE IKB KINASE - Google Patents

ACID 2 - ((2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL) AMINO) -3- (PHENYLPIRIDIN-2-ILAMINO) SUBSTANTIALLY PURE PROPIONIC AS INHIBITOR OF THE IKB KINASE

Info

Publication number
UY28897A1
UY28897A1 UY28897A UY28897A UY28897A1 UY 28897 A1 UY28897 A1 UY 28897A1 UY 28897 A UY28897 A UY 28897A UY 28897 A UY28897 A UY 28897A UY 28897 A1 UY28897 A1 UY 28897A1
Authority
UY
Uruguay
Prior art keywords
inhibitor
substantially pure
phenylpiridin
methylaminopirimidin
ilamino
Prior art date
Application number
UY28897A
Other languages
Spanish (es)
Inventor
Haddad El-Bdaoui
Ritzeler Olaf
David J Aldous
Cox Paul Joseph
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of UY28897A1 publication Critical patent/UY28897A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida al compuesto sustancialmente puro de fórmula (A), o una sal farmacéuticamente aceptable, o solvato de dicho compuesto; a una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz del compuesto de fórmula (A), y un vehículo farmacéuticamente aceptable; y al uso de un compuesto de fórmula (A) que tiene actividad como inhibidor, preferiblemente un inhibidor selectivo, de IkB (IKK), en particular IKK-2, y a métodos relacionados con ello.The present invention is directed to the substantially pure compound of formula (A), or a pharmaceutically acceptable salt, or solvate of said compound; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (A), and a pharmaceutically acceptable carrier; and to the use of a compound of formula (A) having activity as an inhibitor, preferably a selective inhibitor, of IkB (IKK), in particular IKK-2, and related methods.

UY28897A 2004-05-12 2005-05-12 ACID 2 - ((2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL) AMINO) -3- (PHENYLPIRIDIN-2-ILAMINO) SUBSTANTIALLY PURE PROPIONIC AS INHIBITOR OF THE IKB KINASE UY28897A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12

Publications (1)

Publication Number Publication Date
UY28897A1 true UY28897A1 (en) 2005-12-30

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28897A UY28897A1 (en) 2004-05-12 2005-05-12 ACID 2 - ((2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL) AMINO) -3- (PHENYLPIRIDIN-2-ILAMINO) SUBSTANTIALLY PURE PROPIONIC AS INHIBITOR OF THE IKB KINASE

Country Status (23)

Country Link
EP (1) EP1747215A1 (en)
JP (1) JP2007537266A (en)
KR (1) KR20070011483A (en)
CN (1) CN1950359A (en)
AR (1) AR049274A1 (en)
AU (1) AU2005245834A1 (en)
BR (1) BRPI0511029A (en)
CA (1) CA2566213A1 (en)
EC (1) ECSP066992A (en)
GT (1) GT200500111A (en)
IL (1) IL178992A0 (en)
MA (1) MA28553B1 (en)
MX (1) MXPA06012870A (en)
NO (1) NO20065719L (en)
PA (1) PA8633101A1 (en)
PE (1) PE20060269A1 (en)
RU (1) RU2006143758A (en)
SV (1) SV2006002111A (en)
TN (1) TNSN06338A1 (en)
TW (1) TW200605881A (en)
UY (1) UY28897A1 (en)
WO (1) WO2005113544A1 (en)
ZA (1) ZA200608712B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (en) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
DE102004033406A1 (en) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Process for the preparation of the enantiomeric forms of 2,3-diaminopropionic acid derivatives
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
NZ603802A (en) * 2010-04-27 2014-05-30 Hutchison Medipharma Ltd Pyrimidinyl indole compounds
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP7033789B2 (en) 2016-06-29 2022-03-11 オトノミー，インク． Triglyceride ear preparation and its use
CN106588803A (en) * 2016-11-16 2017-04-26 西南科技大学 Novel method for preparing 5-acetylisoxazole

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase

Also Published As

Publication number Publication date
BRPI0511029A (en) 2007-11-27
CA2566213A1 (en) 2005-12-11
NO20065719L (en) 2006-12-12
SV2006002111A (en) 2006-01-30
TNSN06338A1 (en) 2008-02-22
PE20060269A1 (en) 2006-05-11
MXPA06012870A (en) 2007-02-15
PA8633101A1 (en) 2006-01-23
JP2007537266A (en) 2007-12-20
AR049274A1 (en) 2006-07-12
RU2006143758A (en) 2008-06-27
ZA200608712B (en) 2008-06-25
IL178992A0 (en) 2007-03-08
MA28553B1 (en) 2007-04-03
WO2005113544A1 (en) 2005-12-01
AU2005245834A1 (en) 2005-12-01
ECSP066992A (en) 2006-12-29
KR20070011483A (en) 2007-01-24
CN1950359A (en) 2007-04-18
GT200500111A (en) 2006-05-09
EP1747215A1 (en) 2007-01-31
TW200605881A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
UY28897A1 (en) ACID 2 - ((2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL) AMINO) -3- (PHENYLPIRIDIN-2-ILAMINO) SUBSTANTIALLY PURE PROPIONIC AS INHIBITOR OF THE IKB KINASE
AR112074A2 (en) DERIVATIVES OF 2-CARBOXAMIDE-CYCLOAMINE-UREA AS INHIBITORS OF PI-3
EA200701257A1 (en) PYRROPHORASOLES AS A STRONGLY-ACTING KINASE INHIBITORS
ECSP11010948A (en) INHIBITORS OF PROTEIN CINASE ENZYMES ACTIVATED BY
PE20121820A1 (en) (2S, 3R) -N- (2 - ((3-PYRIDINYL) METHYL) -1-AZABICYCLE [2.2.2] OCT-3-IL) BENZOFURAN-2-CARBOXAMIDE, NOVEL SALTS FORMS OF IT, AND METHODS OF USE OF IT
GT200600134A (en) NEW COMPOUNDS OF AMINOSULPHONYL DERIVATIVES
AR049578A1 (en) HYDANTOIN DERIVATIVES, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS
DK1585739T3 (en) Substituted arylcyclopropylacetamides as glucokinase activators
ECSP088258A (en) SERINA PROTEASAS INHIBITORS
BRPI0408353A (en) compound, pharmaceutical composition, methods for the treatment of susceptible neoplasms and for the treatment of viral infections, and, use of a compound
CO6231036A2 (en) SULFUR COMPOUNDS AS INHIBITORS OF THE SERINA PROTEASA NS3 OF THE HEPATITIS C VIRUS
NO20061157L (en) 4-pyramidone derivatives and their use as peptidyl peptide inhibitors
EA200700192A1 (en) PHTHALASINE DERIVATIVES AS PARP INHIBITORS
EA200801291A1 (en) CARBONYLAMINOPYRROPYRAZOLES AS AN EFFICIENT KINAZ INHIBITORS
AR047076A1 (en) PIRROLOTRIAZINE COMPOUNDS AS THYROSINE KINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS
AR055076A1 (en) 1,1-DIOXIDE DERIVATIVES OF 1,4-BENZOTIAZEPIN, PROCEDURE TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN THERAPEUTICS.
CY1109523T1 (en) PHARMACEUTICAL COMPOSITION comprising a benzodiazepine derivative and an RSV Fusion Inhibitor
EA200702498A1 (en) N- (PYRIDIN-2-IL) SULPHONAMIDE DERIVATIVES
EA200800760A1 (en) PYRIDOPYRIMIDINONE INHIBITORS PI3Kα
EA201100795A1 (en) PHARMACEUTICAL COMPOSITION OF EFFICIENT HSG INHIBITOR FOR ORAL ADMINISTRATION
AR051795A1 (en) HYDANTOIN DERIVATIVES METALOPROTEINASE INHIBITORS
AR062797A1 (en) PIPERIDINE DERIVATIVES AS RENINE INHIBITORS, PHARMACEUTICAL COMPOSITIONS.
EA200800302A1 (en) APPLICATION OF DERIVATIVES AND ANALOGUES OF THIAZOLE IN TREATMENT OF CANCER
ECSP077402A (en) DERIVATIVES OF 2-AMIDO-4-PHENYLTIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
EA200970041A1 (en) ACT INHIBITORS (PROTEIN KINASES B)

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120418